MoonLake Immunotherapeutics Capital Reinvestment Ratio
Latest as of June 2021:
2.61x
MoonLake Immunotherapeutics capital reinvestment ratio. MoonLake Immunotherapeutics (MLTX) has a Capital Reinvestment Ratio of 2.61x as of June 2021, meaning it reinvests 3% of its operating cash flow ($6.14K) in capital expenditures ($16.01K). Check MLTX cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
2.61x
Capex / Operating Cash Flow
Operating Cash Flow
$6.14K
USD
Capital Expenditures
$16.01K
USD
Data as of
Jun 2021
Most recent filing
MoonLake Immunotherapeutics Capital Reinvestment Ratio by Year (None–None)
MoonLake Immunotherapeutics capital reinvestment ratio by year from None to None. For the full cash flow conversion analysis, see how efficiently does MoonLake Immunotherapeutics generate cash.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow